Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Qulipta

Chemical Nameatogepant
Dosage FormTablet (oral; 10 mg, 30 mg, 60 mg)
Drug ClassCalcitonin gene-related peptide receptor antagonists
SystemNervous
CompanyAbbVie
Approval Year2021

Indication

  • For the preventive treatment of episodic migraine in adults.
Document TitleYearSource
Qulipta (atogepant) Prescribing Information.2021AbbVie Inc., North Chicago, IL
Document TitleYearSource
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised controlled trials.2022Cephalalgia
Atogepant for the prevention of episodic migraine in adults: a systematic review and meta-analysis of efficacy and safety.2022Neurology and Therapy
Atogepant for migraine prevention: a systematic review of efficacy and safety.2022Clinical Drug Investigation
The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.2022The Journal of Headache and Pain
Atogepant for migraine prevention: a systematic review of efficacy and safety.2022Clinical Drug Investigation
Drug updated on 7/5/2023

More on this drug: Clinical Trials